Antibiotic Therapy for 6 or 12 Weeks for Prosthetic Joint Infection.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] 2. Bone. 2022 Jul;160:116416. doi: 10.1016/j.bone.2022.116416. Epub 2022 Apr 6. Randomized controlled trial of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate in patients with postmenopausal osteoporosis: The TERABIT study. Chiba K(1), Okazaki N(2), Kurogi A(2), Watanabe T(3), Mori A(4), Suzuki N(4), Adachi K(4), Era M(2), Yokota K(2), Inoue T(5), Yabe Y(5), Furukawa K(6), Kondo C(7), Tsuda K(2), Ota S(2), Isobe Y(2), Miyazaki S(2), Morimoto S(8), Sato S(8), Nakashima S(8), Tashiro S(8), Yonekura A(2), Tomita M(2), Osaki M(2). Author information: (1)Department of Orthopedic Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki University Hospital, Japan. Electronic address: kohchiba@estate.ocn.ne.jp. (2)Department of Orthopedic Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki University Hospital, Japan. (3)Watanabe Orthopedic Clinic, Nagasaki University Hospital, Japan. (4)Nagasaki Yurino Hospital, Nagasaki University Hospital, Japan. (5)Juko Memorial Nagasaki Hospital, Nagasaki University Hospital, Japan. (6)Furukawa Orthopedic Clinic, Nagasaki University Hospital, Japan. (7)Kondo Orthopedic Clinic, Nagasaki University Hospital, Japan. (8)Clinical Research Center, Nagasaki University Hospital, Japan. Erratum in Bone. 2022 Sep;162:116484. doi: 10.1016/j.bone.2022.116484. PURPOSE: The effects of daily teriparatide (20 μg) (D-PTH), weekly high-dose teriparatide (56.5 μg) (W-PTH), or bisphosphonates (BPs) on areal bone mineral density (aBMD), bone turnover markers (BTMs), volumetric BMD (vBMD), microarchitecture, and estimated strength were investigated in postmenopausal osteoporosis patients. METHODS: The study participants were 131 women with a history of fragility fractures. They were randomized to receive D-PTH, W-PTH, or BPs (alendronate or risedronate) for 18 months. Dual-energy X-ray absorptiometry (DXA), BTMs, and high-resolution peripheral quantitative CT (HR-pQCT) parameters were evaluated at baseline and after 6 and 18 months of treatment. The primary endpoint was the change (%) in cortical thickness (Ct.Th) after 18 months' treatment compared with baseline. RESULTS: DXA showed that D-PTH, W-PTH, and BPs increased lumbar spine aBMD (+12.0%, +8.5%, and +6.8%) and total hip aBMD (+3.0%, +2.1%, and +3.0%), but D-PTH and W-PTH decreased 1/3 radius aBMD (-4.1%, -3.0%, -1.4%) after 18 months. On HR-pQCT, D-PTH increased trabecular vBMD (Tb.vBMD) at the distal radius and tibia after 18 months (+6.4%, +3.7%) compared with the BPs group, decreased cortical volumetric tissue mineral density (Ct.vTMD) (-1.8%, -0.9%) compared with the other groups, increased Ct.Th (+1.3%, +3.9%), and increased failure load (FL) (+4.7%, +4.4%). W-PTH increased Tb.vBMD (+5.3%, +1.9%), maintained Ct.vTMD (-0.7%, +0.2%) compared with D-PTH, increased Ct.Th (+0.6%, +3.6%), and increased FL (+4.9%, +4.5%). The BPs increased Tb.vBMD only in the radius (+2.0%, +0.2%), maintained Ct.vTMD (-0.6%, +0.3%), increased Ct.Th (+0.5%, +3.4%), and increased FL (+3.9%, +2.8%). CONCLUSIONS: D-PTH and W-PTH comparably increased Ct.Th, the primary endpoint. D-PTH had a strong effect on trabecular bone. Although D-PTH decreased Ct.vTMD, it increased Ct.Th and total bone strength. W-PTH had a moderate effect on trabecular bone, maintained Ct.vTMD, and increased Ct.Th and total bone strength to the same extent as D-PTH. Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved. DOI: 10.1016/j.bone.2022.116416